Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q1
Sell
-165,320
Closed -$4.63M 3111
2016
Q4
$4.63M Buy
165,320
+21,157
+15% +$593K 0.01% 1790
2016
Q3
$3.96M Buy
144,163
+9,940
+7% +$273K ﹤0.01% 1800
2016
Q2
$2.93M Buy
134,223
+12,448
+10% +$272K ﹤0.01% 1884
2016
Q1
$2.72M Buy
121,775
+10,126
+9% +$226K ﹤0.01% 1888
2015
Q4
$3.09M Buy
111,649
+126
+0.1% +$3.48K ﹤0.01% 1831
2015
Q3
$2.88M Sell
111,523
-3,940
-3% -$102K ﹤0.01% 1843
2015
Q2
$2.86M Buy
115,463
+16,216
+16% +$402K ﹤0.01% 1895
2015
Q1
$2.5M Buy
99,247
+19,939
+25% +$503K ﹤0.01% 1932
2014
Q4
$1.86M Buy
79,308
+1,929
+2% +$45.3K ﹤0.01% 2053
2014
Q3
$1.76M Buy
77,379
+3,596
+5% +$81.9K ﹤0.01% 2037
2014
Q2
$1.8M Buy
73,783
+9,106
+14% +$223K ﹤0.01% 2029
2014
Q1
$1.36M Buy
64,677
+15,207
+31% +$321K ﹤0.01% 2140
2013
Q4
$1.18M Buy
49,470
+4,070
+9% +$96.9K ﹤0.01% 2189
2013
Q3
$1M Buy
45,400
+3,800
+9% +$83.7K ﹤0.01% 2211
2013
Q2
$835K Buy
+41,600
New +$835K ﹤0.01% 2268

Other funds holding QGENF

Charles Schwab's QGENF Position: Q1 2017 in Review

Charles Schwab sold out of QIAGEN NV (QGENF) in Q1 2017, closing a stake of 165,320 shares — an estimated $4.63M sold.

Charles Schwab first reported a position in QGENF in Q2 2013 and held it in 15 quarters. The position peaked at $4.63M in Q4 2016. 6 funds tracked by Wall St. Rank hold QGENF as of Q1 2017.

  • Charles Schwab reported no remaining QIAGEN NV position as of Q1 2017 after selling out during the quarter.
  • Charles Schwab sold 165,320 QIAGEN NV shares in Q1 2017, an estimated $4.63M.
  • Charles Schwab first reported a position in QIAGEN NV in Q2 2013 and held it in 15 quarters.
  • Charles Schwab's QIAGEN NV position peaked at $4.63M in Q4 2016.
  • 6 funds tracked by Wall St. Rank held QIAGEN NV as of Q1 2017.

Based on Charles Schwab's 13F filing for Q1 2017, filed 15 May 2017.